References
- Hofmann A. F. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol 2007; 6: 15–27
- Claudel T., Staels B., Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020–30
- Lundasen T., Galman C., Angelin B., Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530–6
- Strack A. M., Myers R. W. Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)?. Endocrinology 2004; 145: 2591–3
- Tomlinson E., Fu L., John L., Hultgren B., Huang X., Renz M., et al. Transgenic mice expressing human fibroblast growth factor‐19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741–7
- Fu L., John L. M., Adams S. H., Yu X. X., Tomlinson E., Renz M., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin‐deficient diabetes. Endocrinology 2004; 145: 2594–603
- Xie M. H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., et al. FGF‐19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 729–35
- Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J. 2007, Epub ahead of print